Rexahn Pharma (RNN) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Rexahn (RNN) Valuation Remains Compelling at Supinoxin, RX-3117 Phase 1 Milestones Near - Roth Capital
May 11, 2015 3:10 PM EDTRoth Capital reaffirms its Buy rating and $3 price target on Rexahn Pharmaceuticals (NYSE: RNN) following Q1 results issued earlier. Rexahn posted Q1 loss of $0.02 per share, versus the consensus loss estimate of $0.03 per share.
Analyst Joseph Pantginis commented, RNN is nearing two clinical milestones with the anticipated data releases from the two dose-escalation... More
